Washington Health

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer2 trials
• Lung cancer2 trials
• Childhood cancers1 trial
• Multiple myeloma1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 35 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Recruiting5 trials
• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• National Cancer Institute (NCI)4 trials
• NRG Oncology2 trials
• Alliance for Clinical Trials in Oncology1 trial
• ECOG-ACRIN Cancer Research Group1 trial

Running trials

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  NCT05946213· Phase 3· NRG Oncology· Source

  Contact: Victor E. Chen (principal investigator)

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

  Contact: Bogdan S. Eftimie (principal investigator)

• Recruiting

  Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  NCT04566328· Phase 3· ECOG-ACRIN Cancer Research Group· Source

  Contact: Matthew E. Tenold (principal investigator)

• Recruiting

  Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  NCT04181060· Phase 3· National Cancer Institute (NCI)· Source

  Contact: Bogdan S. Eftimie (principal investigator)

• Active, not recruiting

  Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

  NCT04310007· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

  NCT04242095· Alliance for Clinical Trials in Oncology· Source

  Contact: Bogdan S. Eftimie (principal investigator)

• Active, not recruiting

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source